New data show AAV-delivered antibody fragments targeting oxidized phosphatidylcholines (PC-OxPL), a species of oxidized phospholipids, thereby neutralizing ...

SOUTH SAN FRANCISCO, CA, USA I May 6, 2025 I IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and ...

New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism ...

Company is advancing a new class of immunomodulators for autoimmune and inflammatory disorders with high unmet medical need- ...

INGELHEIM, Germany I May 6, 2025 I Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the ...

SAN DIEGO, CA, USA I May 5, 2025 I Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development ...

I Frontera Therapeutics announced today that its proprietary recombinant adeno-associated virus (rAAV) gene therapy, FT-003 Injection, has ...

SUZHOU, China I May 5, 2025 I CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, ...

PLAINSBORO, NJ, USA I May 2, 2025 I Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application ...

CAMBRIDGE, MA, USA I April 30, 2025 I Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the first participant has been dosed in the pivotal Phase 3 LUCIDITY ...

SHANGHAI, China I April 30, 2025 I Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, presented 6 study results of innovative drugs and platforms in poster ...